Advertisement

Molecular Neurobiology

, Volume 55, Issue 5, pp 4511–4511 | Cite as

Correction to: Deleterious Effects of VEGFR2 and RET Inhibition in a Preclinical Model of Parkinson’s Disease

  • C. Requejo
  • J. A. Ruiz-Ortega
  • H. Bengoetxea
  • S. Bulnes
  • L. Ugedo
  • J. V. Lafuente
Correction

Correction to: Mol Neurobiol

  https://doi.org/10.1007/s12035-017-0733-x

The authors found a terrible mistake in the manuscript. The legends from the Figs. 5 and 6 are interchanged.

The Fig. 5 should be appeared with the legend from the Fig.6 and Fig. 6 should be appeared with the legend from the Fig. 5.

In addition, the authors also found in the Fig. 6 a mistake in the text referring to the order for (a,b,c,d). Please, find below the correct legend for every figure.

Fig. 5 Vandetanib administration induced activation of caspase-3. The vandetanib group showed significantly increased expression of caspase-3 relative to the control group in the striatum (ac) and in the substantia nigra (bd) (*P ≤ 0.05)

Fig. 6 Molecular changes in survival pathways after vandetanib administration. No differences were found in the activation of Akt (a, b) or ERK1/2 (c, d) in the vandetanib group relative to the control group

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • C. Requejo
    • 1
  • J. A. Ruiz-Ortega
    • 2
  • H. Bengoetxea
    • 1
  • S. Bulnes
    • 1
  • L. Ugedo
    • 2
  • J. V. Lafuente
    • 1
    • 3
    • 4
  1. 1.LaNCE, Department of NeuroscienceUniversity of the Basque, Country (UPV/EHU)LeioaSpain
  2. 2.Department of PharmacologyUniversity of the Basque Country, (UPV/EHU)LeioaSpain
  3. 3.Nanoneurosurgery GroupBioCruces Health Research InstituteBarakaldoSpain
  4. 4.Faculty of Health ScienceUniversidad Autónoma de ChileSantiago de ChileChile

Personalised recommendations